Friday, July 24

Browsing: CSPC

Diagnosis

Talazoparib/Enzalutamide sNDA Receives FDA Priority Review in HRR+ CSPC

By NewsCancerJuly 23, 20260

The FDA has accepted for priority review a supplemental new drug application (sNDA) for talazoparib (Talzenna) in combination with enzalutamide…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.